CN1520284A - Anorexic compsn. comprising calcium acetate - Google Patents

Anorexic compsn. comprising calcium acetate Download PDF

Info

Publication number
CN1520284A
CN1520284A CNA028126742A CN02812674A CN1520284A CN 1520284 A CN1520284 A CN 1520284A CN A028126742 A CNA028126742 A CN A028126742A CN 02812674 A CN02812674 A CN 02812674A CN 1520284 A CN1520284 A CN 1520284A
Authority
CN
China
Prior art keywords
anorexic
composition
group
baseline
calcium acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028126742A
Other languages
Chinese (zh)
Inventor
H・H・沃斯特
H·H·沃斯特
汤姆林森
W·A·汤姆林森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POTCHEFSTROOM UNIV OF CHRISTIAN HIGHER EDUCATION
Original Assignee
POTCHEFSTROOM UNIV OF CHRISTIAN HIGHER EDUCATION
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POTCHEFSTROOM UNIV OF CHRISTIAN HIGHER EDUCATION filed Critical POTCHEFSTROOM UNIV OF CHRISTIAN HIGHER EDUCATION
Publication of CN1520284A publication Critical patent/CN1520284A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides an anorexic composition comprising calcium acetate in a form suitable for oral consumption and absorption in the stomach and small intestines. The anorexic composition includes a flavouring agent for hiding the taste of the calcium acetate, thus rendering the composition suitable for oral consumption and absorption in the stomach and small intestines. The anorexic composition further includes a sweetener and fruit pectin. This invention further relates to a method of treating obesity, including the steps of administering to a person in need thereof the said anorexic composition. Preferably the anorexic composition is administered in the form of a beverage or foodstuff. The method includes the step of administering a sufficient amount of the anorexic composition to the said person in need thereof at least twice daily so that an effective amount of between 3 g and 7 g, preferably 5 g, calcium acetate is administered to the said person.

Description

The anorexic composition that comprises calcium acetate
The present invention relates to a kind of anorexic composition and the purposes in the treatment obesity thereof.
The applicant's south african patent number 97/7300 relates to the medicament of following any symptom in a kind of prevention or the treatment mammal: the fibrin EGCT of atherosclerosis, thrombosis, undesirable high-caliber free radical, undesirable length, undesirable fibrin grumeleuse characteristic, undesirable high-caliber free fatty and obesity and uses thereof.This kit contains the calcium acetate in the medicinal acceptable protective finish, and it has stoped digestion and dissolving in mammiferous harmonization of the stomach small intestinal, but can digest in mammiferous colon or dissolve.This calcium acetate discharges in patient's colon, and does not discharge in the harmonization of the stomach small intestinal.
A shortcoming of the calcium acetate of powder type is its flavor stench, and therefore is not suitable for oral.
Another shortcoming of calcium acetate is, in order to take the treatment effective dose up to 15 with tablet form, oral 3 times of essential every day.This is unpractiaca, and industrial also useless.
The applicant has studied the method for preparation based on the anorexic composition of top reagent, therefore the object of the present invention is to provide a kind of anorexic composition and the purposes in the treatment obesity thereof, and they are improvement of above-identified patent invention disclosed.
According to a first aspect of the invention, provide a kind of anorexic composition, it comprises and is fit to oral and at the calcium acetate of harmonization of the stomach small intestinal absorpting form.
And according to the present invention, this anorexic composition comprises the flavoring agent of hiding the calcium acetate taste, makes said composition be fit to oral thus and absorbs in the harmonization of the stomach small intestinal.
Based on the quality of anorexic composition, calcium acetate can account for 54%-89.9%.
Based on the quality of anorexic composition, flavoring agent can account for 5%-20%.
This anorexic composition can comprise sweeting agent.
Based on the quality of anorexic composition, sweeting agent can account for 5%-25%.
Anorexic composition can comprise pectin.
Based on the quality of anorexic composition, pectin can account for 0.1%-1%.
This anorexic composition can be water-soluble powder type.
According to a second aspect of the invention, provide a kind of fat method for the treatment of, comprised step: the people who the anorexic composition of first aspect of the present invention is needed it.
This anorexic composition can beverage or the form of food give.
This method can comprise step: need its described people with this anorexic composition of capacity every day at least twice, so that give the effective dose of this people 3g-7g calcium acetate.
Give the effective dose of described people 5g calcium acetate twice preferred every day.
By following non-limiting example a preferred embodiment of the present invention is described now:
Embodiment 1
1. method
1.1 research design
The main purpose of this research is to measure the influence that lose weight of anorexic composition of the present invention to fat object (meals of caloric restriction).Select the design of a kind of double blinding, placebo, wherein two parallel group object is accepted this meals: be supplemented with this anorexic composition and micronutrient mixture, perhaps only be supplemented with the micronutrient mixture and this anorexic composition not.The meals that the 3rd winding is supplemented with the placebo product continued for 12 weeks.By the baseline between each group and the variation of end value among the baseline in each group relatively and end value and the design, and compare, make the applicant can estimate the influence of this anorexic composition and micronutrient mixture with placebo group is observed.
1.2 participation object
Enlist 120 fat volunteers and in the applicant's metabolism unit, screen.Use following standard:
Comprise standard: sex; Age is at 21-45 between year; Body Mass Index (BMI)＞27kg/m 2Be ready to be obedient to treatment;
Exclusion standard: pregnancy; Suckling; Any chronic disease; Use chronic medicine and/or nutritional supplement.
This research approach and step are explained to these volunteers, and 80 object signature information of same expectation that satisfy this standard are single.These 80 objects (9 male and 71 women) are divided into 3 groups at random also require during this 12 week research, main life style to be changed, except relating to meals and supplement therapy.The mean age that during baseline this is three groups, body weight, height and BMI are shown in table 4.2 and 4.3.Because therefore the negligible amounts of male's object does not estimate the difference of reacting between the masculinity and femininity.
1.3 intervene
1.3.1 meals
The low-fat diet that heat is restricted (defat) gives each participant.The food type of these meals and every deal are through selecting so that the 5000-6000 Kilojoule is provided every day.These meals and the principle that loses weight are explained to each object.Food is replaced by the low fat substitute in the meals list that object is often not edible.Preparation is selected from the nutrient analysis of picked-up every day of the meals that give the women.This analysis shows with these meals even the caloric intake amount can be reduced to and be lower than 5000 Kilojoule that this depends on every deal.Yet with this mental retardation intake, if do not use micronutrient fill-in (not allowing) in this research, the micronutrient intake will descend so.Require the object of these participations to accept these meals as much as possible.They will be apprised of, if their weight does not alleviate, will be the signal that they are not obedient to the meals rule so.These meals according to low fat principle and less part can reach shortage of energy at least 2000 Kilojoule every day, convert the 4.4kg that loses weight in (84 days) time in 12 weeks to, and this is accepted.
1.3.2 fill-in
In conjunction with these meals, give twice fill-in each every day in (great majority are chosen in before breakfast and the lunch) before two meals three group.This fill-in must be dissolved in 5ml (1) several seconds in one glass of water by stirring by powder constituent, drinks immediately in ante cibum then.The composition of this fill-in is shown in table 1.The 1st winding is subjected to the mixture of micronutrient mixture and anorexic composition of the present invention.The 2nd winding is subjected to the placebo fill-in be made up of lactose, pigment and flavoring agent.The 3rd winding is subjected to and the 1st group of identical prescription, does not just contain anorexic composition.Every day, the dosage of 2 5ml made the 1st group to absorb the 5g anorexic composition, and the 1265mg calcium that absorbs in addition every day is provided.0.1%-1% pectin is joined in the 1st group and the 3rd group of compositions.
Table 1: every day 10mL dosage the composition of fill-in
Component The 1st group of anorexic composition The 2nd group of placebo The 3rd group of micronutrient
Calcium acetate ????5g ??- ????-
Lactose ????- ??5.5g ????5g
Micronutrient mixture chromium (GTF) vanadium potassium ????100μg ????50μg ????5mg ??- ????100μg ????50μg ????5mg
Marine extracts ????200mg ??- ????200mg
Choline ????150mg ??- ????150mg
Sweeting agent ????0.36g ??0.36g ????0.36g
Flavoring agent and coloring agent ????0.54g ??0.54g ????0.54g
Sorbitol ????2g ??2g ????2g
Cumulative volume ????5.00mL ??5.00mL ????5.00mL
1.4 measure
With regard to screening technique, object is filled in demographic and medical history application form.They weigh, measure height and calculate Body Mass Index.Carry out baseline determination in that day that the object of these 3 random group is accepted the meals of caloric restriction and accepted its fill-in.These mensuration comprise somatometry, a 24-hour meals picked-up recalls and blood is sampled to measure biochemical variable.After 12 weeks, repeat this baseline determination to obtain end value.In addition, the metabolism unit that these objects are visited the applicant once in a week to be weighing, the compliance of monitor treatment, and accept its fill-in.The used method of all these variablees of operable mensuration and normal range/separation (cut point) is summarized in table 2.
Table 2: measure the used method of variable: baseline and end value
Variable Method Normal range
Somatometry:
Height (m) Diastimeter is not worn footwear, correct position
Body weight (kg) Precision Health Scale; Indoor wear only
Body Mass Index (kg/m 2) With kg/m 2Calculate 18-25
Waistline (cm) Not tensile plastic tape is measured
Hip circumference (cm) “??????????????????“
Middle upper-arm circumference (cm) “??????????????????“
Blood pressure Tycos becomes human sphygomanometer 120/80mmHg
Body temperature Braun heat scan ear-thermometer 37℃
The consensus data Application form
The meals data Recalled application form in 24-hour
Blood sample With butterfly (21G) and syringe venous blood from cephalic vein
Serum Prepare by solidification blood
Blood plasma Contain the blood preparation (1: 4) of Chinese holly edge hydrochlorate
Hemoglobin (mmol/L) Use the cyanomethemoglobin colorimetry of whole blood A 8.7-11.2 individual male 7.5-9.9 women
Hematocrit (%) Centrifuging is used heparinization blood A 39-49 male 33-44 women
Blood plasma fibrinogen (g/L) Clauss, ACL 200 methods 250-300
Serum total cholesterol (mmol/L) DAX collection of illustrative plates: enzymatic colorimetric ＜4.0
LDL-cholesterol (mmol/L) Calculate ＜3.4
HDL-cholesterol (mmol/L) DAX collection of illustrative plates: enzymatic colorimetric ＞1.0
Triglyceride (mmol/L) DAX collection of illustrative plates: enzymatic colorimetric 0.8-1.50
1.5 statistical analysis
Use SPSS program (the 9th edition), with these data computerizations, cleaning (two monitoring) is also analyzed.Use pairing the sample survey relatively baseline and the end value of each group.Because these groups are little, therefore use nonparametric test, the Kruskal-Wallis check, the relatively variation from the baseline to the end value between each group.
1.6 ethics is considered
The Ethics Committee of the Applicant ratifies this research (EthicsCommittee OOM22).All object signature written consent lists.Voluntarily but satisfying the people who comprises standard selects to add the Lipid Clinic of the Applicant in theMetabolic Unit and is used to screen serum lipids body and meals suggestion.
2. result
2.1 object
Table 3 has shown in 80 objects of enlisting have 5 (all being the women) to withdraw from (the 1st group 3 are organized each one for other two).Two objects in the 1st group are found to accept these meals; Other 3 have other incoherent medical problem, cause them further not participate in.During studying and when finishing, note compliance (acceptability) to meals and product.Although are " blindnesses " still, show that the object that they are not obedient to this product is elected to be " not henchman " to these treatments.Table 3 has shown 10 not henchmans in the 1st group, the 2nd group has 2, and the 3rd group has 4.
Table 3: the quantity that participates in object
The 1st group The 2nd group The 3rd group Add up to
Enlist and randomized sum ????27 ????26 ????27 ????80
Withdraw from * ????3 ????1 ????1 ????5
Henchman # not ????10 ????2 ????4 ????16
The henchman ????14 ????23 ????22 ????59
The 1st group: anorexic composition
The 2nd group: placebo
The 3rd group: micronutrient mixture, (the micronutrient mixture does not have calcium acetate)
Table 4 has shown that the mean age difference of 3 groups is not remarkable, henchman and henchman's age differences is not remarkable yet in each group.
Table 4: in the henchman of each group and not henchman's age and height
Variable The 1st group The 2nd group The 3rd group
????C ????NC ????C ????NC ????C ????NC
Number of objects ????14 ????10 ????23 ????2 ????22 ????4
Age (year) ??37.3±8.2 ??33.1±8.7 ??36.2±8.1 ??38.5±9.2 ??37.5±6.6 ??41.7±4.7
Height (cm) ??1.66±0.11 ??1.64±0.62 ??1.64±0.84 ??1.72±0.82 ??1.67±0.73 ??1.66±0.89
C=henchman (referring to following)
NC=is henchman's (referring to following) not
The 1st group: anorexic composition+meals
The 2nd group: placebo+meals
The 3rd group: micronutrient mixture+meals
2.2 the variation of body weight and Body Mass Index
Table 5 has shown that the average weight of the henchman in all 3 groups and Body Mass Index (BMI) all significantly reduce.Table 5 has shown that also the 1st group alleviates 9.2kg, significantly greater than the 2nd group (alleviating 5.8kg).The 1st group BMI reduces 3.3kg/m 2, significantly greater than the 2nd group of (2.1kg/m 2) and the 3rd group of (1.9kg/m 2).Positive according to expectation, the not henchman of each group loses weight less than the henchman's.
Table 5: henchman and not henchman's body weight and Body Mass Index
Variable The 1st group The 2nd group The 3rd group
????C ????NC ????C ????NC ????C ????NC
Number of objects ????14 ????10 ????23 ????2 ????22 ????4
Body weight (kg): baseline SD ????97.1 a????±25.6 ????91.4 ????±17.3 ????92.7 b????±18.6 ????84.8 ????±17.9 ????89.8 c????±13.7 ????86.5 ????±24.0
Body weight (kg): final SD ????87.9 a????±22.2 ????89.8 ????±17.5 ????86.9 b????±18.0 ????82.5 ????±21.9 ????84.3 c????±13.4 ????83.7 ????±23.1
Body weight change ????9.2 g ????1.6 ????5.8 g ????2.3 ????5.5 ????2.8
BMI(kg/m 2): baseline SD ????34.8 d????±6.7 ????33.7 ????±4.7 ????34.3 e????±15.7 ????28.6 ????±3.0 ????32.1 f????±5.2 ????31.2 ????±7.5
BMI(kg/m 2): final SD ????31.5 d????±5.9 ????33.1 ????±4.6 ????32.2 e????±5.8 ????27.8 ????±4.5 ????30.2 f????±5.3 ????30.3 ????±7.3
BMI changes ????3.3 h1 ????0.6 ????2.1 h ????0.8 ????1.9 i ????0.9
C=henchman (referring to following)
NC=is henchman's (referring to following) not
The BMI=Body Mass Index
The SD=standard deviation
A, b, c with same-sign ... significant difference (p≤0.05):
Group is interior, the pairing sample survey; Variation between the group, Kruskal-Wallis checks (non-parametric)
The 1st group: anorexic composition+meals
The 2nd group: placebo+meals
The 3rd group: micronutrient mixture+meals
2.3 the variation that body encloses
Table 6 has shown that henchman's body weight change is accompanied by waistline, hip circumference, thigh circumference and middle upper-arm circumference in all 3 groups significantly to be reduced.The hip circumference and middle upper-arm circumference in the 2nd group, bigger these reductions of the 1st group, although not too remarkable.
Table 6: the henchman and not henchman's body enclose
Variable First group Second group The 3rd group
????C ??NC ????C ????NC ????C ????NC
Number of objects ????14 ??10 ????23 ????2 ????22 ????4
Waistline (cm): baseline SD ????98.2 a????18.9 ??96.8 ??±23.2 ????95.1 ????±15.3 ????96.5 b????±10.6 ????94.0 ????±13.8 ????89.7 ????±5.7
Waistline (cm): final SD ????92.2 a????±17.3 ??91.5 ??±16.7 ????89.6 ????±13.8 ????94.0 b????±11.3 ????88.8 ????±11.1 ????87.0 ????±7.2
Waistline changes ????6.0 ??5.3 ????5.5 ????2.5 ????5.2 ????2.7
Hip circumference (cm): baseline SD ????117.2 c????±10.8 ??115.4 ??±8.4 ????118.3 d????±2.8 ????110.0 ????±2.8 ????112.8 e????±7.7 ????113.0 ????±14.9
Hip circumference (cm): final SD ????111.4 c????±9.5 ??113.6 ??±7.6 ????112.6 d????±11.1 ????105.5 ????±0.71 ????108.5 e????±8.2 ????110.0 ????±17.3
Hip circumference changes ????5.8 ??1.8 ????5.7 ????4.5 ????4.3 ????3.0
Thigh circumference (cm): baseline SD ????66.6 f????±9.1 ??68.1 ??±4.9 ????65.8 g????±6.0 ????58.5 ????±2.1 ????64.1 h????±3.9 ????68.0 ????±7.9
Thigh circumference (cm): final SD ????58.5 f????±5.1 ??62.9 ??±3.9 ????60.4 g????±6.5 ????55.5 ????±0.7 ????58.1 h????±4.8 ????64.7 ????±8.1
Thigh circumference changes ????8.1 ??5.2 ????5.4 ????3.0 ????6.0 ????3.3
In go up hip circumference (cm): baseline SD ????33.1 l????±13.9 ??32.4 ??±2.5 ????35.5 l????±7.8 ????32.0 ????±4.2 ????32.9 k????±2.5 ????33.0 ????±3.0
In go up hip circumference (cm): final SD ????30.6 l????±3.0 ??30.5 ??±2.4 ????31.6 l????±3.6 ????30.5 ????±5.0 ????30.9 k????±2.6 ????30.7 ????±3.8
In go up hip circumference and change ????2.5 ??1.9 ????3.9 ????1.5 ????2.0 ????2.3
C=henchman (referring to following)
NC=is henchman's (referring to following) not
The BMI=Body Mass Index
The SD=standard deviation
A, b, c with same-sign ... significant difference (p≤0.05):
Group is interior, the pairing sample survey; Variation between the group, Kruskal-Wallis checks (non-parametric)
The 1st group: anorexic composition+meals
The 2nd group: placebo+meals
The 3rd group: micronutrient mixture+meals
2.4 the variation of hematology's variable
Table 7 has shown the variation of hemoglobin, hematocrit and blood plasma fibrinogen.Henchman in all 3 groups shows that hemoglobin significantly reduces, although average end value is still in the normal range of 8.7-11.2mmol/L (male) and 7.5-9.9mmol/L (women).
Hematocrit significantly reduces in the 1st group and the 2nd group.Between baseline period, the 2nd group of value than the 1st group reduces more remarkable.Yet, not remarkable on the henchman's of 3 groups variation 1.1 and the 4.0mmol/L statistics.
Table 7 has also shown the variation of blood plasma fibrinogen.But the blood plasma fibrinogen has on the little statistics among the henchman of the 1st group and the 2nd group increases significantly (0.13 and 0.12g/L).Not henchman in these two groups has very little and inapparent reduction.
The blood plasma fibrinogen has little significant reduce (0.05g/L) in the 3rd group the object of this product but be obedient to.
Table 7: henchman and hematology's variable of henchman not in each group
Variable First group Second group The 3rd group
????C ????NC ????C ????NC ????C ????NC
Number of objects ????14 ????10 ????23 ????2 ????22 ????4
Hemoglobin mmol/L baseline SD ????10.2 a????±1.2 ????10.3 ????±1.7 ????9.6 b????±1.1 ????9.6 ????±0.1 ????9.8 c????±1.6 ????9.9 ????±0.5
The final SD of hemoglobin mmol/L ????9.3 a????±1.3 ????9.0 ????±1.0 ????9.0 b????±1.1 ????10.1 ????±1.4 ????8?8 c????±1.1 ????8.6 ????±1.8
Hemoglobin changes ????0.9 ????1.3 ????0.6 ????0.5↑ ????1.0 ????1.3
Hematocrit %:% baseline SD ????43.4 ????±3.7 ????43.6 ????±4.1 ????41.8 de????±2.1 ????42.5 ????±3.5 ????43.7 fe????±3.2 ????42.0 ????±1.0
Hematocrit %: final SD ????42.3 ????±3.7 ????40.9 ????±4.6 ????39.6 d????±4.5 ????42.0 ????±2.8 ????39.7 f????±4.5
Hematocrit changes ????1.1 ? ????2.7 ? ????2.2 ? ????0.5 ? ????4.0 ?
Blood plasma fibrinogen g/L: baseline SD ? ????3.69 g????±0.63 ? ? ? ????3.57 ????±0.80 ? ? ? ????3.52h ????±0.72 ? ? ? ????3.68 ????±0.26 ? ? ? ????3.51 l????±0.87 ? ? ? ????3.54 ????±1.15 ? ?
Blood plasma fibrinogen g/L: final SD ? ????3.82 g????±1.11 ? ? ? ????3.54 ????±0.74 ? ? ? ????3.64 h????±0.74 ? ? ? ????3.62 ????±0.42 ? ? ? ????3.46 l????±0.89 ? ? ? ????3.58 ????±0.70 ? ?
The blood plasma fibrinogen changes ????0.13↑ ? ? ????0.03↓ ? ? ????0.12↑ ? ? ????0.06↓ ? ? ????0.05↓ ? ? ????0.04↑ ? ?
-can not the acquisition value
C=henchman (referring to following)
NC=is henchman's (referring to following) not
The BMI=Body Mass Index
The SD=standard deviation
A, b, c with same-sign ... significant difference (p≤0.05):
Group is interior, the pairing sample survey; Variation between the group, Kruskal-Wallis checks (non-parametric)
The 1st group: anorexic composition+meals
The 2nd group: placebo+meals
The 3rd group: micronutrient mixture+meals
2.5 the variation of serum lipids body and lipoprotein
Table 8 has shown the variation of serum total cholesterol, LDL-and HDL-cholesterol and S-TG.Although these variation neither ones are remarkable statistically between the henchman organizes interior or organizes, it should be noted that in T-CHOL and LDL-cholesterol and slightly reduce.The HDL-cholesterol does not change.Yet the 1st group S-TG demonstration increases to 1.68mmol/L from 1.19.This increase is not remarkable statistically, but can present clinical remarkable increase in some henchmans.
Table 8: henchman and average (standard deviation) nutrient intake amount * of henchman not in each group
Nutrition, (unit) and RDA First group Second group The 3rd group
????C ??NC ????C ????NC ????C ??NC
Energy (kJ) baseline is final ????7413±2178 ????5239±2602 ??5700±2890 ??5178±2833 ????7371±2876 ????4866±2030 ????9974±4341 ????4922±1445 ????6719±3010 ????5204±2626 ??7566±5064 ??7273±3680
Total protein (g) baseline is final ????63.4±22.3 ????57.5±23.2 ??57.3±28.3 ??56.5±30.3 ????66.8±30.2 ????51.1±17.4 ????78.6±45.7 ????53.3±19.0 ????62.5±23.8 ????55.1±20.5 ??81.5±45.9 ??65.0±17.8
Vegetable protein (g) baseline is final ????19.4±5.0 ????18.4±8.4 ??15.6±5.9 ??15.0±9.5 ????21.1±11.9 ????14.2±8.4 ????19.1±10.3 ????12.3±3.3 ????18.4±7.9 ????15.4±5.2 ??16?9±12.0 ??21.8±7.4
Total fat (g) baseline is final ????65.3±26.2 ????46.8±30.0 ??50.0±34.2 ??43.8±29.4 ????61.0±25.3 ????37.7±24.5 ????77.2±53.5 ????46.1±31.7 ????59.2±39.8 ????42.3±34.9 ??78.9±59.2 ??62.9±28.6
SATFAT (g) baseline is final ????22.8±9.4 ????14.6±9.7 ??18.0±11.3 ??16.7±11.9 ????21.4±9.8 ????14.0+9.4 ????24.9±16.1 ????16.6±7.8 ????19.5±12.6 ????15.3±12.4 ??35.9±27.7 ??19.0±5.9
MUFAT (g) baseline is final ????22.1±9.6 ????14.5±8.8 ??16.3±11.4 ??14.1±10.7 ????20.4±9.7 ????12.0±7.9 ????28.0±19.3 ????17.6±16.2 ????20.1±13.3 ????14.3±13.3 ??25.5±20.3 ??20.2±4.7
PUFAT (g) baseline is final ????13.8±7.5 ????10.1±5.9 ??11.3±9.6 ??9.0±6.1 ????13.6±9.4 ????8.1±7.0 ????16.9±13.7 ????8.3±5.9 ????12.2±12.8 ????8.5±8.7 ??10.4±7.3 ??18.7±18.7
Cholesterol (mg) baseline is final ????287±213 ????162±106 ??175±135 ??205±202 ????206±130 ????158±117 ????290±123 ????140±83 ????205±181 ????171±149 ??241±127 ??315±84
Alcohol (g) baseline is final ????4.8±12.9 ????3.3±8.1 ??3.3±10.4 ??1.8±5.7 ????2.8±10.3 ????2.4±6.4 ????21.6±30.6 ????- ????2.69±9.0 ????4.4±8.6 ??7.5±13.0 ?????-
Carbohydrate (g) baseline is final ????206±61 ????129.9±68.5 ??152±64 ??138.2±89.0 ????212±101 ????137±57.7 ????289±136 ????124.0±3.8 ????183±79 ????140.5±65.6 ??160±128 ??212.4±136.1
Sugar (g) baseline that adds is final ????55.3±38.2 ????12.8±20.8 ??22.6±19.9 ??20.6±22.7 ????50.3±50.4 ????22.0±23.1 ????107.2±1.5 ????23.4±22.7 ????42.1±37.5 ????24.9±25.6 ??24.7±30.3 ??51.9±72.6
Total fiber (g) baseline is final ????17.2±3.8 ????13.2±6.5 ??11.5±5.0 ??11.5±6.8 ????17.2±9.0 ????12.3±5.3 ????15.8±9.7 ????12.3±7.1 ????16.7±8.4 ????11.0±5.1 ??19.6±13.9 ??13.8±6.0
Calcium (mg) baseline is final ????576±214 ????496±495 ??422±239 ??426±292 ????640±342 ????433±290 ????1123±1276 ????199±72 ????516±329 ????458±169 ??873±743 ??504±197
The final magnesium of ferrum (mg) baseline (mg) ????12.3±5.1 ????10.9±10.7 ??8.7±5.0 ??8.8±3.9 ????9.0±2.9 ????7.8±3.8 ????10.9±5.0 ????6.3±0.3 ????12.4±6.6 ????8.6±4.1 ??10.0±4.5 ??9.0±2.1
Baseline is final ????275.5±74.1 ????224.5±82.3 ??192.6±87.3 ??179.0±75.4 ????259.0±78.1 ????198.3±75.4 ????310.0±215.0 ????157.0±26.9 ????243.7±102.7 ????200.7±59.1 ??323.3±190.1 ??244.7±49
Phosphorus (mg) baseline is final ????941.9±245.7 ????847.5±413.9 ??736.6±381.7 ??787.1±388.3 ????1036.1±431.5 ????747.3±302.7 ????1358±1067.7 ????622.0±60.8 ????907.5±389.8 ????772.7±229.3 ??1255.0±907. ??1 ??901.0±188.6
Nutrition, (unit) and RDA The 1st group The 2nd group The 3rd group
????C ????NC ????C ????NC ??C ????NC
Potassium (mg) baseline is final ????2594±865.9 ????1980.4±464.8 ??1962.7±879. ????3 ?1590.7±657. ????4 ????2492±692.5 ????1958.6±851.3 3866.0±2723. ??8 1739.5±221.3 ??2291.4±1094.6 ??1940.6±656.0 ??3045.7±176 ????4.5 ??2329.0±595. ????5
Sodium (mg) baseline is final ????1713.0±674.1 ????1253.5±801.3 ??1231.0±703. ????0 ??1360.3±872. ????7 ????1492.4±848.7 ????973.1±633.2 1710.0±1298. ??3 639.0±396.0 ??1497.7±838.3 ??1225.1±644.2 ??1758.3±176 ????5.2 ??1029.3±323. ????6
Zinc (mg) baseline is final ????8.9±.3.2 ????7.0±.3.6 ????7.5±4.0 ????7.6±4.6 ????8.6±3.2 ????7.5±4.3 ????13.2±9.5 ????6.1±1.2 ????8.5±2.9 ????7.3±2.8 ????11.7±8.2 ????9.2±2.1
Copper (mg) baseline is final ????1.3±0.3 ????0.9±0.4 ????0.9±0.4 ????1.2±1.1 ????1.3±0.6 ????0.9±0.3 ????1.2±0.4 ????0.8±0.01 ????1.1±0.4 ????1.0±0.7 ????1.4±1.2 ????1.1±0.4
Chromium (mg) baseline is final ????57.6±48.2 ????53.1±19.0 ????47.3±36.0 ????45.5±41.8 ????58.7±33.8 ????43.2±27.0 ????142.5±65.0 ????46.5±49.6 ????53.5±25.7 ????43.2±31.1 ????61.0±46.2 ????51.5±22.1
Selenium (mg) baseline is final ????62.9±52.6 ????40.8±23.5 ????27.8±19.4 ????48.6±39.5 ????52.3±37.6 ????27.2±13.4 ????42.3±5.0 ????26.5±11.2 ????42.9±30.6 ????43.2±35.2 ????49.7±33.5 ????38.0±16.1
Iodine (mg) baseline is final ????48.9±30.0 ????33.0±12.9 ????32.0±19.0 ????32.8±24.9 ????35.9±15.6 ????31.0±15.1 ????60.0±2.8 ????17.5±12.0 ????37.1±27.0 ????29.3±21.2 ????52.0±38.4 ????43.7±11.0
Vitamin A (RE) baseline is final ????1240.9±1535.5 ????565.8±615.7 ????346.5±262.2 ????877.4±1186. ????4 ????1308.3±1396.7 ????943.1±1493.1 ????787.0±784.9 ????1405.0±1158. ????2 ????1009.5±1457.3 ????452.2±633.9 ????1866.7±157 ????4.6 ????257.3±156.5
The thiamine baseline is final ????1.0±0.3 ????0.9±0.5 ????0.8±0.4 ????0.8±0.6 ????0.9±0.5 ????0.8±0.5 ????1.2±0.9 ????0.7±0.3 ????1.0±0.4 ????0.8±0.6 ????1.2±1.0 ????0.9±0.1
The riboflavin baseline is final ????1.5±1.0 ????1.0±0.8 ????0.9±0.7 ????1.1±0.9 ????1.1±0.5 ????1.0±0.6 ????1.6±1.3 ????0.6±0.07 ????1.2±0.7 ????1.0±0.5 ????1.5±1.1 ????1.0±0.2
The nicotinic acid baseline is final ????18.9±6.9 ????19.3±10.2 ????16.4±9.0 ????14.7±7.0 ????17.1±7.9 ????15.1±8.2 ????15.5±5.2 ????18.0±9.1 ????19.3±10.9 ????15.2±7.2 ????15.3±8.3 ????15.3±4.4
The vitamin B12 baseline is final ????4.2±2.9 ????2.3±1.6 ????2.4±1.6 ????7.8±10.8 ????3.3±3.3 ????2.4±1.4 ????2.9±1.4 ????1.9±1.5 ????2.9±1.4 ????4.3±5.3 ????3.7±1.9 ????3.4±0.7
The vitamin C baseline is final ????96.5±65.6 ????43.6±32.7 ????101.2±107.0 ????59.0±60.1 ????135.1±96.5 ????66.1±65.7 ????146.0±103.2 ????78.0±67.9 ????129.1±204.9 ????68.3±61.3 ????121.3±100.1 ????267.7±208.7
The vitamin D baseline is final ????4.7±3.9 ????1.7±2.0 ????1.8±2.4 ????2.7±3.5 ????2.2±2.0 ????2.5±2.6 ????8.5±3.0 ????1.1±1.4 ????2.7±3.1 ????1.8±2.1 ????1.0±0.2 ????4.3±0.9
The vitamin E baseline is final ????13.3±7.1 ????7.5±3.8 ????8.7±5.9 ????9.2±7.5 ????9.4±4.1 ????8.2±6.4 ????20.7±13.0 ????5.6±2.0 ????9.0±5.7 ????7.9±4.7 ????7.1±4.3 ????19.4±13.8
The vitamin B6 baseline is final ????1.4±0.6 ????0.9±0.2 ????1.3±0.6 ????1.0±0.6 ????1.1±0.4 ????1.3±0.9 ????1.7±1.0 ????1.2±0.3 ????1.5±0.6 ????1.0±0.6 ????1.6±1.0 ????1.1±0.07
The folic acid baseline is final ????214.9±69.4 ????180.8±131.6 ????164.4±105.9 ????163.1±100.7 ????208.0±121.1 ????160.3±100.8 ????176.0±36.8 ????92.0±1.4 ????163.1±73.4 ????152.4±73.2 ????189.7±160.2 ????214.0±13.5
2.6 meals intake
Table 8 has provided in 3 groups henchman and henchman's average nutrient intake amount not.These intakes are to use 24-hour recall method to measure the baseline and the end value of this scheme.Table 8 has shown with baseline to be compared, and the 1st group is reported in final intake and reduces 2174kJ, the 2nd group of intake reduction 2505kJ, the 3rd group of intake reduction 1515kJ.Table 8 has shown that also the reduction of these caloric intakes mainly is because fat is lower and the Sugar intake of adding.
Table 9: henchman and henchman's serum lipids body (mmol/L) not in each group
Variable First group Second group The 3rd group
????C ????NC ????C ????NC ????C ????NC
Number of objects ????14 ????10 ????23 ????2 ????22 ????4
T-CHOL: baseline SD ????5.03 ????±1.22 ????5.47 ????±1.38 ????5.32 ????±0.80 ????5.45 ????±1.61 ????5.41 ????±1.26 ????5.81 ????±0.93
T-CHOL: final SD ????4.96 ????±0.93 ????5.23 ????±0.98 ????4.95 ????±0.76 ????6.21 ????±0.76 ????5.26 ????±2.61 ????5.61 ????±0.77
The variation of T-CHOL ????0.07 ????0.24 ????0.37 ????0.76↑ ????0.15 ????0.20
LDL-C baseline SD ????3.48 ????±0.89 ????3.75 ????±1.39 ????3.63 ????±0.74 ????3.45 ????±1.15 ????3.62 ????±0.99 ????3.77 ????±0.82
The final SD of LDL-C ????3.24 ????±0.54 ????3.54 ????±0.92 ????3.36 ????±0.58 ????4.25 ????±1.86 ????3.47 ????±1.00 ????3.59 ????±0.50
The variation of LDL-C ????0.24 ????0.21 ????0.27 ????0.80↑ ????0.15 ????0.18
HDL-C baseline SD ????1.17 ????±0.42 ????1.28 ????±0.31 ????1.25 ????±0.36 ????1.07 ????±0.61 ????1.25 ????±0.27 ????1.39 ????±0.20
The final SD of HDL-C ????1.11 ????±0.33 ????1.28 ????±0.32 ????1.17 ????±0.33 ????1.14 ????±0.35 ????1.23 ????±0.28 ????1.33 ????±0.12
The variation of HDL-C ????0.06 ????0.00 ????0.08 ????0.07↑ ????0.02 ????0.06
The HDL-C% baseline SD of TC ????23.9 ????±8.8 ????24.7 ????±8.5 ????23.7 ????±7.6 ????19.7 ????±1.3 ????24.7 ????±9.2 ????24.3 ????±3.7
The final SD of the HDL-C% of TC ????22.5 ????±5.1 ????25.2 ????±7.0 ????23.7 ????±6.4 ????18.8 ????±2.2 ????24.9 ????±8.2 ????23.8 ????±1.1
The variation of HDL-C ????1.4 ????0.5↑ ????00.0 ????0.9 ????0.2↑ ????0.5
Triglyceride baseline SD ????1.19 ????±0.68 ????0.99 ????±0.57 ????0.98 ????±0.38 ????2.08 ????±0.47 ????1.22 ????±0.92 ????1.43 ????±0.45
The final SD of triglyceride ????1.68 ????±1.29 ????0.91 ????±0.44 ????0.92 ????±0.36 ????1.82 ????±0.88 ????1.23 ????±1.03 ????1.53 ????±0.20
The variation of triglyceride ????0.49↑ ????0.08 ????0.06 ????0.26 ????0.01↑ ????0.10↑
The LDL-C=low-density lipoprotein cholesterol
The HDL-C=HDL-C
C=henchman (referring to following)
NC=is henchman's (referring to following) not
The BMI=Body Mass Index
The SD=standard deviation
A, b, c with same-sign ... significant difference (p≤0.05):
Variation in the group, between the pairing sample survey group, Kruskal-Wallis checks (non-parametric)
The 1st group: anorexic composition+meals
The 2nd group: placebo+meals
The 3rd group: micronutrient mixture+meals
3. discuss
3.1 henchman and henchman not
The main purpose of this research is to compare with the placebo group of accepting meals+non-activity placebo, estimates the influence that loses weight of fat object of the meals of the restricted heat of two kinds of treatments (two kinds of potential agent that lose weight, goods, fill-in or products) butt joints.In this research, measure meals compliance difficulty always.But because the influence of two kinds of specific productss of mensuration is studied the compliance that determines to measure the product of giving (and placebo product) when finishing during therefore the individual when object is weighed speaks face to face weekly and in 12 weeks.This difference between " henchman " and " not henchman " should not obscured with " respondent and not respondent ".Under one situation of back, be obedient to treatment and show that still the object of expecting the result usually is described as " not respondent ".
Since use report to the compliance of this product rather than this result (promptly losing weight) as difference henchman and the standard between the henchman not, therefore relatively in each group these two subgroups and relatively the henchman of 3 groups can estimate the effect of different product effectively.Yet the group of not being obedient to this product also alleviates certain weight (be respectively 1.6,2.3 and 2.8kg), and this illustrates that these objects have accepted the meals of this caloric restriction to a certain extent.The 2nd group lose weight illustrates that also it is acceptable to a certain extent that meals are obedient to.This hint is not obedient to these products person and may be had the problem of being obedient to these meals.The motivation level that loses weight in these objects may there are differences.
Fat object adheres to that the meals of caloric restriction are problems, and the caloric intake of underestimating the obese people is the phenomenon (7) of an acceptance.Therefore the meals intake of using report is as the existing problems of measuring of being obedient to.In any case, report that at baseline with when research finishes the meals intake of these objects is shown in adnexa 4.The meals intake of report is those of the previous day, and is not custom intake (can measure by food frequency application form).Underestimated fat object owing to known, so can reduce the danger of underestimating between recall period at 24 hours.
Reported that the average energy shortage is maximum, the 3rd group of minimum for the 2nd group.Compare significant difference with the 1st group, although the 1st group of maximum that loses weight, the not bigger shortage of energy of report.This hints that this anorexic composition also may have the influence (not only picked-up) to energy expenditure.Yet this research does not design measures its mechanism.
3.2 lose weight
The weight saving that the object Bi Di that presentation of results shown in the table 5 is the 1st group is 2 groups is more remarkable, and its BMI is more remarkable than the henchman's of the 2nd group and the 3rd group reduction.
In the time of 12 weeks (84 days), group 2 and 3 henchmans on average alleviate 5.8 and 5.5kg, and this explanation these objects in the meantime realizes about 220400 and the shortage of energy of 209000 Kilojoule.This converts the every day shortage of energy to is between the 2488-2624 Kilojoule.The 1st group objects alleviates other 3.4kg, be meant 12 all self-energys in addition short 129200 Kilojoule or every day shortage of energy 1538 Kilojoule.In a word, the 1st group objects is realized average short 4162 Kilojoule every day.
As what mentioned in 5.1, the problem of need answering is whether what to cause by this anorexic composition be because result's (being obedient to the meals of this caloric restriction preferably) of intake reduction due to the appetite inhibiting to " add " effect of losing weight, perhaps does this anorexic composition have independent effect to metabolism? calcium when being reported in high dose (a kind of material in the anorexic composition) can play anoretic (8).Whether the calcium (1265mg/ days) of the additional amount that provides by anorexic composition is also determined appetite-suppressing.In any case as if the object that the micronutrient mixture is taken in prudent suggestion should be accepted LCD.
3.3 body encloses
Henchman's body encloses (table 6) significantly reduction in all 3 groups.If use the mean value calculation waistline of waistline and hip circumference: as if the hip circumference ratio, the reduction of waistline is slightly larger than the reduction of hip circumference.The result is the waistline in the 1st group, the 2nd group and the 3rd group: hip circumference is respectively 0.032,0.007 and 0.015 than reducing slightly.Can use waistline: hip circumference is than difference male's sample or the upper body is fat and women's sample or lower body obesity (1).Male's value 〉=1.0 and women's value 〉=0.85 are referred to as male's sample obesity (1).All three groups all have 〉=0.800 baseline value.The 1st group is reduced that big (from 0.838 to 0.806) may be owing to lose weight bigger.
4 conclusions
4.3 main the discovery
Therefore, the main discovery of this research is to adhere to taking every days in 12 weeks the subject representation work of twice of this anorexic composition to alleviate, and its BMI significantly reduces than the BMI that takes placebo or micronutrient mixture object regularly.And, by presenting calcium acetate, make this anorexic composition further feasible and industrial available to be fit to oral for example liquid beverage form.
4.4 conclusion
Can reach a conclusion from these results, this anorexic composition is a kind of effective slimming reagent, and the object that helps to accept the caloric restriction meals is reduced bigger body weight.Only do not have the group of micronutrient mixture itself not observe this influence owing to there is anorexic composition, so this anorexic composition make that really body weight further alleviates.
4.5 recommend
Therefore this anorexic composition can be recommended as a kind of slimming effectively fill-in, and it will help to accept the fat object of caloric restriction meals, than only there are these meals to lose weight biglyyer.By presenting calcium acetate,, the invention provides a kind of industrial available and acceptable product in fact by hiding its stench taste with drinkable and good to eat goods form.
Therefore the applicant's prediction, anorexic composition of the present invention and the fat method of treatment are a kind of effective slimming methods.
Obviously, under the scope that does not deviate from additional claims, can carry out various changes to anorexic composition of the present invention and uses thereof.
Document
1.World?Health?Organization.Obesity.Preventing?and?managing?theglobal?epidemic.Report?of?a?WHO?consultation?on?obesity.Geneva，WHO，1998：1-276.
2.Walker?ARP.Obesity?outlook：hopeful?or?hopeless？Editorial.SAJEpidemiol?Infect?2000；15(4)：87-88.
3.Rosenbaum?M，Leibel?RL，Hirsch?J.Obesity.N?Eng?J?Med?1997；337：396-407.
4.Walker?ARP.Obesity：the?new?pill-any?practicable?improvements？S?AfrJ?Clin?Nutr?2000；13(1)：4-6.
5.Veldman?FJ，Nair?CH，Vorster?HH，Vermaak?WJ，Jerling?JC，OosthuizenW，Venter?CS.Possible?mechanisms?through?which?dietary?pectin?influencesfibrin?network?architecture?in?hypercholesterolaemic?subjects.ThrombosisResearch?1999；93(6)：253-264.
6.Potchefstroom?University?for?Christian?Higher?Education：Patent.
7.Kruger?HS.The?puzzle?of?obesity?ion?African?women：contributing?factorsand?associated?risk?factors.Ph.D.thesis.PU?vir?CHO.1999：1-210.
8.Reynolds?JEF?ed.Martindale.The?extra?pharmacopoeia.London，Pharmaceutical?Press?1993；853-855.
9.Anderson?JW.Short-chain?fatty?acids?and?lipid?metabolism：humanstudies.In：Cummings?JH，Rombeau?JL，Sakata?T.Eds.Physiolbgical?andclinicala?spects?of?short-chain?fatty?acids.Cambridge?University?Press，1995：509-523.
10.Venter?CS，Vorster?HH.Possible?metabolic?consequences?offermentation?in?the?colon?of?humans.Medical?hypothesis，1989；29(3)：161-166.
11.Meyer?BJ，Meij?HS，Labuschagne?CJJ?et?al.Eds.Die?fisiologiese?basisvan?geneeskunde.Pretoria，HAUM?1988；24.1-24.3.
12.Vorster?HH，Badenhorst?C，Barnard?HC，Walker?ARP，Kruger?MM，vanJaarsveld?P.Effects?of?weight?reduction?on?plasma?fibrinogen?levels?andother?metabolic?variables?in?obese?women.S?Afr?J?Clin?Nutr?1989；2(2)：8-15.
13.Vorster?HH，Cummings?JH，Jerling?JC.Diet?and?haemostatic?processes.Nutrition?research?reviews?1997；10：115-135.
14.Vorster?HH，Venter?CS.Why?fibrinogen?should?be?measured?as?part?ofthe?coronary?heart?disease?risk?profile.S?Afr?Med?J?1993；83：309-310.
15.Mann?J.Cardiovascular?diseases.In：Mann?J.Truswell?AS.Eds.Essentials?of?human?nutrition.Oxford，Oxford?University?Press?1998：279-307.
16.Wolmarans?P，Oosthuizen?W.Eat?fat?sparingly-implication?for?healthand?disease.S?Afr?J?Clin?Nutr?2001；14(3)：S48-S55.
17.Venter?CS，Vorster?HH，Cummings?JH.Effects?of?dietary?propionate?oncarbohydrate?and?lipid?metabolism，in?healthy?volunteers.Am?JGastroenterol?1990；85：549-553.

Claims (15)

1, a kind of anorexic composition comprises and is fit to oral and at the calcium acetate of the form of the little intestinal absorption of harmonization of the stomach.
2, anorexic composition as claimed in claim 1 comprises a kind of flavoring agent of hiding calcium acetate stench taste, makes said composition be fit to oral thus and absorbs in the harmonization of the stomach small intestinal.
3, as the anorexic composition of claim 1 or claim 2, wherein based on the quality of anorexic composition, calcium acetate accounts for 54%-89.9%.
4, anorexic composition as claimed in claim 2, wherein based on the quality of anorexic composition, flavoring agent accounts for 5%-20%.
5, as each anorexic composition of front claim, comprise a kind of sweeting agent.
6, anorexic composition as claimed in claim 5, wherein based on the quality of anorexic composition, sweeting agent accounts for 5%-25%.
7, as each anorexic composition of front claim, comprise pectin.
8, anorexic composition as claimed in claim 7, based on the quality of anorexic composition, pectin accounts for 0.1%-1%.
9, as each anorexic composition of front claim, be water-soluble powder type.
10, a kind ofly treat fat method, comprise step: the people who claim 1-9 and 14 each anorexic composition is needed it.
11, as the method for claim 10, wherein this anorexic composition can beverage or the form of food give.
12, as the method for claim 10 or 11, comprise step: need its described people with this anorexic composition of capacity every day at least twice, so that give the calcium acetate of this people 3g-7g effective dose.
13,, wherein give the calcium acetate of described people 5g effective dose every day for twice as the method for claim 12.
14, a kind of as described herein basically and anorexic composition of enumerating.
15, a kind of method of the as described herein basically and treatment obesity enumerated.
CNA028126742A 2001-05-29 2002-05-29 Anorexic compsn. comprising calcium acetate Pending CN1520284A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200104418 2001-05-29
ZA2001/4418 2001-05-29

Publications (1)

Publication Number Publication Date
CN1520284A true CN1520284A (en) 2004-08-11

Family

ID=25589179

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028126742A Pending CN1520284A (en) 2001-05-29 2002-05-29 Anorexic compsn. comprising calcium acetate

Country Status (2)

Country Link
CN (1) CN1520284A (en)
WO (1) WO2002096393A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989166B2 (en) * 2001-12-20 2006-01-24 N.V. Nutricia Soft drink replacer
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070082025A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for achieving and maintaining weight loss
US20070082114A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for reducing weight
CA2658465C (en) 2006-07-21 2016-06-14 Stephen C. Tarallo Liquid compositions of calcium acetate
CN113057139B (en) * 2021-04-16 2023-07-07 扬子江药业集团江苏龙凤堂中药有限公司 Infantile anorexia animal model caused by high calorie and high fat diet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006774C2 (en) * 1996-08-14 1998-09-28 Univ Potchefstroom Anti-atherosclerosis and anti-thrombotic agent and its uses.

Also Published As

Publication number Publication date
WO2002096393A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
Alessandro et al. Effects of twenty days of the ketogenic diet on metabolic and respiratory parameters in healthy subjects
CN101248900B (en) Novel solid sport drink medicinal granules
Antonio Paoli et al. Effects of 30 days of ketogenic diet on body composition, muscle strength, muscle area, metabolism, and performance in semi-professional soccer players
CN106690290A (en) High dietary fiber full nutrition special application formula food and preparing method thereof
WO2005123108A2 (en) Advanced vitamins and protein based nutritional supplements
EP2076256B1 (en) Meal replacement compositions and weight control method
EP3010357B1 (en) Administration of a food composition product
WO2017027599A1 (en) Composition comprising sacha inchi protein in combination with other plant proteins
CN1520284A (en) Anorexic compsn. comprising calcium acetate
US20180200285A1 (en) Dietary prebiotic supplement and related method
Watanabe et al. A Cross-Sectional Study on the Effects of Long Term Very Low Protein Diets in Patients with Chronic Kidney Disease Serum and Urine DEXA and Amino Acid Profiles
KR20050115017A (en) Functional food composition having obesity control effect and the preparation method thereof
Szpanowska-Wohn et al. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by haemodialysis
US11141429B2 (en) Composition and use of macro-minerals to lower postprandial glycemic response and reduce body weight
US20190200624A1 (en) Nutritional compositions and methods of using same
Shaykhova et al. Efficacy in assessing the nutritional and biological value of ginger gelatin capsules in patients with Covid-19
Mironenko et al. Magnesium (Mg, Magnesium)–description, effect on the body, the best sources of magnesium
Becherer Associations Between Dietary Plant Protein and Animal Protein with Other Nutrient Intakes
Lichtenstein Optimal Nutrition Guidance for Older Adults
Özkaya et al. A Preventive Effect of the Mediterranean Diet on Cardiovascular Disease Risk in Type 2 Diabetics (Premedic Trial)
Devi et al. IMPACT ON AGING AND AGE-ASSOCIATED DISEASES WITH SPECIAL REFERENCE TO FOOD AND NUTRITION
Tirona Chromium Supplementation And The Essentiality Of Chromium To Human Nutrition: A Narrative Review
Mahata Can Diet Reverse Ageing? Diet and Ageing: Role and Relation
Eliseeva Phosphorus (P)–Body & Health Importance+ Top 30 Sources
Loss Autoimmune Disease & Allergies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication